| 1 |
王淑珍，丁惠国．肝硬化顽固性腹水新的治疗模式及理念[J]．中华肝脏病杂志，2017，25(4): 249-253.
|
| 2 |
Runyon BA.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 [J]. Hepatology, 2013, 57(4): 1651-1653.
|
| 3 |
Shiegto K, Kawaguchi T, Niizeki T, et al.Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report [J]. Oncol Lett, 2016, 11(5): 3205-3209.
|
| 4 |
Rai N, Singh B, Singh A, et al.Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study [J]. Liver Int, 2017, 37(3): 406-414.
|
| 5 |
Ming Z, Smyth DD, Lautt WW.Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine [J]. Hepatology, 2002, 35(1): 167-175.
|
| 6 |
Jia JD, Xie W, Ding HG, et al.Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study [J]. Ann Hepatol, 2017, 16(1): 123-132.
|
| 7 |
Hiramine Y, Uto H, Imamura Y, et al.Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema[J]. Hepatol Res, 2017, 47(6): 542-557.
|
| 8 |
Hirai K, Shimomura T, Moriwaki H, et al.Risk factors for hypernatremia in patients with short-and long-term tolvaptan treatment [J]. Eur J Clin Pharmacol, 2016, 72(10): 1177-1183.
|
| 9 |
Cárdenas A1, Ginès P, Marotta P, et al.Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis [J]. J Hepatol, 2012, 56(3): 571-578.
|
| 10 |
Yamada T, Ohki T, Hayata Y, et al.Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis [J]. Clin Drug Invest, 2016, 36(10): 829-835.
|
| 11 |
Okita K, Sakaida I, Okada M, et al.A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis [J]. J Gastroenterol, 2010, 45(9): 979-987.
|
| 12 |
Kurosaki M, Izumi N. Tolvaptan for the Treatment of Refractory Ascites [J]. Int Med, 2016, 55(20): 2909-2910.
|
| 13 |
Kumars S, Berl T. Vasopressin antagonists in the treatment of water-retaining disorders [J]. Sem Nephrol, 2008, 28(3): 279-288.
|
| 14 |
King LS, Agre P. Pathophysiology of the aquaporin water channels [J]. Annu Rev Physiol, 1996, 58: 619-648.
|
| 15 |
Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans [J]. Lancet, 2008, 371(9624): 1624-1632.
|
| 16 |
Mori T, Ohsaki Y, Oba-Yabana I, et al.Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure [J]. Hepatol Res, 2017, 47(1): 11-22.
|
| 17 |
Xue H, Tang X. Effect of vasopressin on Na(＋)-K(＋)-2Cl(－)cotransporter(NKCC)and the signaling mechanisms on the murine late distal colon [J]. Eur J Pharmacol, 2016, 771: 241-246.
|
| 18 |
Gerbes AL, Gulberg V, Gines P, et al.Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial [J]. Gastroenterol, 2003, 124(4): 933-999.
|
| 19 |
Sakaida I, Kawazoe S, Kajimura K, et al.Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial [J]. Hepatol Res, 2014, 44(1): 73-82.
|
| 20 |
Akiyama S, Ikeda K, Sezaki H, et al.Therapeutic effects of short-and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis [J]. Hepatol Res, 2015, 45(11): 1062-1070.
|
| 21 |
Kogiso T, Tokushige K, Hashimoto E, et al.Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis [J]. Hepatol Res, 2016, 46(3): E194-E200.
|
| 22 |
Sakaida I, Terai S, Kurosaki M, et al.Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis(START study)[J]. Hepatol Res, 2017, 47(11): 1137-1146.
|
| 23 |
Pose E, Sola E, Piano S, et al.Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience [J]. Am J Med, 2017, 130(3): 372-375.
|
| 24 |
Vandergheynst F, Brachet C, Heinrichs C, et al.Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports [J]. Nep Clin Pract, 2012, 120(3): c168-c172.
|
| 25 |
ESTEVA-FONT C, BACCARO M E, FERNANDEZ-LLAMA P, et al.Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome [J]. Hepatology, 2006, 44(6): 1555-1563.
|
| 26 |
Iwasa M, Ishihara T, Hasegawa H, et al.Cirrhosis-related hyponatremia and the role of tolvaptan [J]. Hepatol Res, 2015, 45(10): E163-E165.
|
| 27 |
Cordaba J, Garcia-Martinez R, Simon-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence [J]. Metab Brain Dis, 2010, 25(1): 73-80.
|
| 28 |
Guevara M, Baccardo ME, Ríos J, et al.Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration [J]. Liver Int, 2010, 30(8): 1137-1142.
|
| 29 |
Iwasa M, Takei Y. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia [J]. Hepatol Res, 2015, 45(12): 1155-1162.
|
| 30 |
Tanabe N, Takami T, Fujisawa K, et al.Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model [J]. J Clin BiochemNutr, 2017, 61(1): 53-59.
|
| 31 |
Yakushijin K, Yamamoto K, Kurata K, et al.Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation [J]. Int J Hematol, 2013, 97(2): 284-286.
|
| 32 |
Yi S, Jeon H, Yoon SH, et al.Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15-to 60-mg single doses to healthy Korean men [J]. J Cardiovasc Pharmacol, 2012, 59(4): 315-322.
|
| 33 |
Okita K, Kawazeo S, Hasebe C, et al.Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial [J]. Hepatol Res, 2014, 44(1): 83-91.
|
| 34 |
Sakaida I, Yamashita S, Kobayashi T, et al.Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema [J]. J Int Med Res, 2013, 41(3): 835-847.
|
| 35 |
Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management [J]. Hepatology, 2008, 48(3): 1002-1010.
|